Compare SLBT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLBT | NVAX |
|---|---|---|
| Founded | N/A | 1987 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2025 | 1996 |
| Metric | SLBT | NVAX |
|---|---|---|
| Price | $2.69 | $8.96 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 72.2K | ★ 3.5M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $2.54 | $6.20 |
| 52 Week High | $6.25 | $11.85 |
| Indicator | SLBT | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 64.09 |
| Support Level | $2.54 | $8.42 |
| Resistance Level | $3.40 | $10.10 |
| Average True Range (ATR) | 0.17 | 0.36 |
| MACD | 0.05 | 0.17 |
| Stochastic Oscillator | 0.00 | 91.14 |
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.